Citizens Maintains Market Outperform on Zymeworks, Raises Price Target to $39
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Citizens analyst Reni Benjamin maintains Zymeworks (NASDAQ:ZYME) with a Market Outperform and raises the price target from $32 to $39.
Citizens analyst Reni Benjamin maintains Zymeworks (NASDAQ:ZYME) with a Market Outperform and raises the price target from $32 to $39.
